PriZm Therapeutics
1 known investors
PriZm Tx develops treatments for rare genetic disorders, with a focus on MCT8 Deficiency (AHDS), an ultra-rare condition affecting boys. Its lead candidate is a first-in-class therapy for this disorder.
Investors · 1
Competitors · 2
by search overlap
Oup8 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.
Fdna7 shared keywordsFDNA develops AI-powered image analysis and decision-support tools that help parents, school nurses, and pediatric and genetic specialists detect developmental delays, genetic disorders, and rare diseases earlier. Its technology, including a crowdsourced phenotypic database and products like Face2Gene, connects patients with healthcare providers, pharmaceutical companies, and CROs across more than 130 countries.
Companies competing with PriZm Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does PriZm Therapeutics do?
- PriZm Tx develops treatments for rare genetic disorders, with a focus on MCT8 Deficiency (AHDS), an ultra-rare condition affecting boys. Its lead candidate is a first-in-class therapy for this disorder.
- Who are PriZm Therapeutics's investors?
- PriZm Therapeutics's investors include The Innovation Space.